MEDINDIA
English
हिन्दी
Español
français
中文
Email
3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Etomidate.
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etomidate.
Acebutolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.
Acepromazine
The risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.
Alfaxalone
The risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Etomidate.
Alphaprodine
The risk or severity of adverse effects can be increased when Etomidate is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Etomidate.
Alprenolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.
Amineptin
Amineptine may decrease the antihypertensive activities of Etomidate.
Amisulpride
The risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.
Amitriptyline
Amitriptyline may decrease the antihypertensive activities of Etomidate.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Etomidate.
Amoxapine
Amoxapine may decrease the antihypertensive activities of Etomidate.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etomidate.
Articaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Etomidate.
Atenolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.
Azelastine
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Etomidate.
Barbital
The risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.
Benoxinate
The risk or severity of adverse effects can be increased when Etomidate is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Etomidate is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Benzocaine.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.
Betaxolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.
Bisoprolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
Bopindolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.
Brexpiprazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Etomidate.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Etomidate.
Bromperidol
The risk or severity of adverse effects can be increased when Etomidate is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Etomidate.
Brotizolam
The risk or severity of adverse effects can be increased when Etomidate is combined with Brotizolam.
Bupivacaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.
Bupranolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.
Buprenorphine
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Etomidate.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Etomidate.
Butamben
The risk or severity of adverse effects can be increased when Etomidate is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Etomidate.
Carbamazepine
The risk or severity of adverse effects can be increased when Carbamazepine is combined with Etomidate.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Etomidate.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Etomidate.
Carteolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.
Carvedilol
Etomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.
Celiprolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Celiprolol.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Etomidate.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etomidate.
Chlormethiazole
The risk or severity of adverse effects can be increased when Etomidate is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Etomidate is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Etomidate.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etomidate.
Chlorprothixene
The risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etomidate.
Citalopram
The risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.
Clemastine
The risk or severity of adverse effects can be increased when Clemastine is combined with Etomidate.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Etomidate.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Etomidate.
Clobazam
The risk or severity of adverse effects can be increased when Clobazam is combined with Etomidate.
Clomipramine
Clomipramine may decrease the antihypertensive activities of Etomidate.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Etomidate.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Etomidate.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Etomidate.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Etomidate.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Etomidate.
Cocaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Etomidate.
Cyclobenzaprine
Cyclobenzaprine may decrease the antihypertensive activities of Etomidate.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Etomidate.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Etomidate.
Dapiprazole
The risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Etomidate.
Desipramine
Desipramine may decrease the antihypertensive activities of Etomidate.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Etomidate.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Etomidate is combined with Desvenlafaxine.
Deutetrabenazine
The risk or severity of sedation and somnolence can be increased when Etomidate is combined with Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etomidate.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Etomidate is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Etomidate.
Dibucaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Etomidate.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etomidate.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Etomidate.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etomidate.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etomidate.
Dothiepin
Dosulepin may decrease the antihypertensive activities of Etomidate.
Doxepin
Doxepin may decrease the antihypertensive activities of Etomidate.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Duloxetine
The risk or severity of adverse effects can be increased when Etomidate is combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Etomidate.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Etomidate.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Etomidate.
Escitalopram
The risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.
Esmolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Etomidate.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Etomidate.
Ethanol
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Etomidate.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Etomidate.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Etomidate is combined with Etifoxine.
Ezogabine
The risk or severity of adverse effects can be increased when Ezogabine is combined with Etomidate.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Etomidate.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Etomidate.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Etomidate.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Etomidate.
Flunarizine
The risk or severity of adverse effects can be increased when Flunarizine is combined with Etomidate.
Flunitrazepam
The risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.
Fluoxetine
The risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Etomidate.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Etomidate.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Etomidate.
Fluspirilene
The risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Etomidate.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etomidate.
Fosphenytoin
The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Etomidate.
Fospropofol
The risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Etomidate.
Glutethimide
The risk or severity of adverse effects can be increased when Etomidate is combined with Glutethimide.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Etomidate.
Halazepam
The risk or severity of adverse effects can be increased when Etomidate is combined with Halazepam.
Haloperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Etomidate.
Halothane
The risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.
Heroin
The risk or severity of adverse effects can be increased when Etomidate is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.
Hydrocodone
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Etomidate.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Etomidate.
Imipramine
Imipramine may decrease the antihypertensive activities of Etomidate.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Etomidate.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Etomidate.
Ketazolam
The risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.
Labetalol
Etomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Etomidate.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Etomidate.
Levobupivacaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Etomidate is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Etomidate.
Levodopa
The risk or severity of adverse effects can be increased when Levodopa is combined with Etomidate.
Levomethadyl
The risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Etomidate is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Etomidate.
Lidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.
Lithium
The risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Etomidate.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.
Lormetazepam
The risk or severity of adverse effects can be increased when Etomidate is combined with Lormetazepam.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Etomidate.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate.
Magnesium Sulfate
The therapeutic efficacy of Etomidate can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Etomidate can be increased when used in combination with Magnesium sulfate.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Etomidate.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Etomidate.
Melatonin
The risk or severity of adverse effects can be increased when Etomidate is combined with Melatonin.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Etomidate.
Mephobarbital
The risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Etomidate.
Mesoridazine
The risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Etomidate.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Etomidate.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Etomidate is combined with Methadyl Acetate.
Methapyrilene
The risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Etomidate.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Etomidate.
Methotrimeprazine
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Etomidate.
Metoprolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Etomidate is combined with Melperone.
Metyrosine
Etomidate may increase the sedative activities of Metyrosine.
Mianserin
The therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Etomidate.
Milnacipran
The risk or severity of adverse effects can be increased when Etomidate is combined with Milnacipran.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Mirtazapine
Mirtazapine may decrease the antihypertensive activities of Etomidate.
Molindone
The risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Etomidate.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Nadolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Etomidate.
Nebivolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Nebivolol.
Nefazodone
The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Etomidate.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Etomidate.
Norflurane
The risk or severity of adverse effects can be increased when Etomidate is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Etomidate is combined with Normethadone.
Nortriptyline
Nortriptyline may decrease the antihypertensive activities of Etomidate.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Etomidate.
Ondansetron
The risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.
Opipramol
Opipramol may decrease the antihypertensive activities of Etomidate.
Opium
The risk or severity of adverse effects can be increased when Etomidate is combined with Opium.
Orphenadrine
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Etomidate.
Oxprenolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Etomidate.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Etomidate.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Etomidate.
Paraldehyde
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Etomidate.
Paroxetine
The risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.
Penbutolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Etomidate.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Perazine
The risk or severity of adverse effects can be increased when Etomidate is combined with Perazine.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Etomidate.
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Etomidate.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Etomidate is combined with Phenoxyethanol.
Phenytoin
The risk or severity of adverse effects can be increased when Phenytoin is combined with Etomidate.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Etomidate.
Pindolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Etomidate.
Pirinitramide
The risk or severity of adverse effects can be increased when Etomidate is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Pizotifen is combined with Etomidate.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Etomidate.
Practolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Practolol.
Pramipexole
Etomidate may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Etomidate is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Etomidate can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Prilocaine.
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Etomidate.
Procaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.
Promazine
The risk or severity of adverse effects can be increased when Promazine is combined with Etomidate.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Etomidate.
Proparacaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Proparacaine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Etomidate.
Propoxyphene
The risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.
Propranolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.
Protriptyline
Protriptyline may decrease the antihypertensive activities of Etomidate.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Etomidate.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Etomidate.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Etomidate.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Etomidate.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Etomidate.
Remoxipride
The risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Etomidate.
Ropinirole
Etomidate may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.
Rotigotine
Etomidate may increase the sedative activities of Rotigotine.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Etomidate.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Etomidate.
Sertindole
The risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.
Sertraline
The risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Etomidate.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Sotalol
Etomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Etomidate.
Sulpiride
The risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.
Suvorexant
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Talinolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Talinolol.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Etomidate.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Etomidate.
Tetracaine
The risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Thalidomide
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal
The risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Etomidate.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Etomidate.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Etomidate.
Tianeptine
Tianeptine may decrease the antihypertensive activities of Etomidate.
Tiapride
The risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.
Timolol
Etomidate may increase the atrioventricular blocking (AV block) activities of Timolol.
Timolol Anhydrous
Etomidate may increase the atrioventricular blocking (AV block) activities of Timolol.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Etomidate.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Etomidate.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Etomidate.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.
Tranylcypromine
The risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Etomidate.
Triazulenone
The risk or severity of adverse effects can be increased when Etomidate is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etomidate.
Triflupromazine
The risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.
Trimipramine
Trimipramine may decrease the antihypertensive activities of Etomidate.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Etomidate.
Urethane
The risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.
Venlafaxine
The risk or severity of adverse effects can be increased when Etomidate is combined with Venlafaxine.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Etomidate.
Vortioxetine
The risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Etomidate.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Etomidate.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.
Zolpidem
Etomidate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Etomidate.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Etomidate.
Zotepine
The risk or severity of adverse effects can be increased when Etomidate is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etomidate.
